R&D planning
Development plan, preclinical and clinical strategy. Regulatory roadmap and technical gates. Manufacturing and quality, including CMC (chemistry, manufacturing and controls).
Preclinical · CMC · Gates
Your development plan, with what every decision gate costs and the money that is really there.
That cost stays up to date as the plan moves, and you load the whole plan in one session.
Book a diagnostic sessionRun the free readiness checkFirst call, no cost. You leave with your priorities ranked.
Toxicity study
Preclinical
€185K
▲ on track
Series A close
Investment
€2.4M
▲ 8% vs plan
The science can be brilliant and the project still be a mess.
No plan, no legal structure, and a story that does not survive three questions from an investor.
01
No development plan
Promising scientific data, but no clear development plan.
02
Fronts pulling apart
Science, regulation, market and funding pulling in different directions.
03
No legal structure
No legal structure for the spin-off, the founders, the IP or the contracts.
04
Projections on demand
Financial projections built because a spreadsheet asked for them.
05
Roadmaps without gates
Roadmaps with no gates, no ranked risks and no owners.
06
Not a company yet
A publication is not a company. A patent is not a round.
A biotech is not built on good science alone. It is built on decisions taken in the right order.
A bad call on one front moves the other two.
A legal decision changes the investment. A market hypothesis changes the development plan. A regulatory strategy changes what the company is worth. We plan the three services as one.
Financial planning
Feasibility, market and competition. Business plan, financial model and funding strategy. The narrative an investor reads.
Market · Runway · Funding
Legal advice
Spin-offs and shareholder agreements. Intellectual property, contracts and licensing. Technology transfer and compliance.
Spin-off · Patents · Contracts
We also produce the scientific communication around it: video, event broadcasting, web design and training material. The science has to land with the investors, partners and regulators who read it.
Strategic advisory, end to end.
The same three services, in the same order, with a senior name behind each. It runs from the science and its protection to the business case the investor signs.
01
R&D planning
SCIENCE · REGULATORY · CMCFrom the promising experiment to the asset roadmap. We sequence the target product profile, the evidence strategy and the regulatory route. It runs from preclinical to first dose in humans.
- Target product profile (TPP)
- Development roadmap with its decision gates
- Preclinical and clinical plan
- Regulatory strategy
- CMC and manufacturing plan
- Risk map
02
Financial planning
STRATEGY · FINANCE · FUNDINGWe build the case that raises capital. Market and competition, business model, financial plan and funding strategy. It runs from the public grant to the Series A.
- Feasibility and market analysis
- Competitive landscape
- Business plan and financial model
- Runway and scenarios
- Funding strategy, public and private
- Investor memo, pitch deck and data room
03
Legal advice
IP · CORPORATE · COMPLIANCEWe protect the asset and structure the company. Freedom to operate, patents and licensing. Company structure, and the regulatory and data compliance an investor will audit.
- Company structure and shareholder agreements
- Spin-off and technology transfer
- IP strategy and patent plan
- Key contracts: confidentiality, research, manufacturing and licensing
Programs
Packaged advisory, with a defined scope.
We do not sell blocks of hours. Every program has an objective, a scope and a set of deliverables. You know what you get, and when.
Venture Scan
A fast read of the project: how mature it is in science, law, market and funding. The critical decisions come out ranked.
Venture Blueprint
The development and business plan, sequenced gate by gate. Milestones, risks, costs and owners. Ready to execute.
Legal Biotech Kit
The legal structure that makes the technology fundable: company, shareholder agreement, IP and key contracts.
Investor Readiness Pack
The case an investor signs off. Business plan, financial model and investor memo. Pitch deck and data room.
Maturity & Investability Report
An independent report on the maturity and investability of the asset, with a roadmap to close the gaps.
Fractional PMO
Part-time project direction: the project management office, without a full-time hire. We track milestones, runway and risk, and report to the team and its investors.
How we work.
First we think. Then we structure. Then we execute. We leave the magic to LinkedIn.
Diagnostic
We map the asset, its stage and its legal structure. Then the funding, the risks and the priorities.
Critical decision map
We identify what is actually blocking progress. The block can sit in the science, the law, the money or the market.
Development and business plan
A sequenced plan. It carries milestones and gates, costs and owners, risks and deliverables.
Execution and expert support
We stay on the key calls: development and manufacturing, intellectual property and contracts, funding and investors.
Tracking and reporting
We review progress, runway, milestones and risks. Then we write the reports for the team, the board and its investors.
Toxicity study
Preclinical
€185K
▲ on track
PCT filing
Intellectual property
€32K
● pending
Scientific advice meeting
Regulatory · AEMPS
Mar '27
▼ 6 wks
Series A close
Investment
€2.4M
▲ 8% vs plan
A hybrid team for a hybrid problem
Building a biotech takes science and regulation, law and business, funding and market. That is why the team is put together the way it is.
Chief scientific officer. Over 25 years in pharma and biotech: drug development, CMC and scientific strategy.
Science · CMC
Lawyer. Contracts, corporate and R&D law, pharmaceutical and administrative law. Biotech legal support.
Legal · IP
Business development, strategy, market and access. Customer strategy in pharma and biotech.
Business · Market
Rubén Íñiguez Pérez
Digital training, audiovisual production and scientific communication.
Digital · Communication
Network of specialist collaborators
- Manish Sharma · Manufacturing · CMC
- Jaume Ruiz · Development · Business
- Karen Sánchez · Legal · Data
- Leire Zúñiga · Clinical trials
- Naiara Pineda · Finance
Frequently asked questions
Do you only work with biotech startups?
No. We work with researchers, spin-offs and biotech startups, and with pharma and biotech companies. The projects can be in health, advanced therapies, medical devices or related technologies.
At what stage does it make sense to talk to you?
Early, above all. Before the spin-off, during preclinical, or while you raise funding. The sooner the critical decisions are put in order, the less the chaos costs.
How is an engagement structured?
Through programs with a defined scope and deliverables, or as bespoke support. We almost always start with a diagnostic. It ranks the priorities before you commit to larger work.
Do you help with funding?
Yes. Business plan, financial model and investor narrative. Pitch deck, investor memo and data room. Term sheets, and public or private funding strategy.
Do you handle legal work?
Yes. Corporate structure, spin-offs and shareholder agreements. Intellectual property, contracts and licensing. Technology transfer, sector regulation, data protection and due diligence.
Do you replace the scientific team?
No. We complement it with development judgement and legal structure, market sense and funding. The science stays with the team. We bring the order.
Contact
Promising science and too many loose pieces?
Tell us where the project stands, on a call or through the form. We will come back with what it needs next: development, legal, market or funding.
Book a callOne call can save months aimed at the wrong question.
Av. Navarra 14, 26001 Logroño, Spain
+34 686 678 490 · partners@adbaio.com · LinkedIn